Affinium Pharmaceuticals Welcomes Dr. Barry Hafkin as Chief Medical Officer
TORONTO & AUSTIN, Texas--(BUSINESS WIRE)--Affinium Pharmaceuticals, Inc., a privately held developer of a novel class of highly potent oral antibacterial therapeutics announces the addition of Dr. Barry Hafkin as its Chief Medical Officer. Dr. Hafkin will lead Affinium’s clinical development program and establish Affinium’s new regulatory team based in Austin Texas.